GlassScriptPhysician profile
Sonya M Walsh
NPI 1619532066
$5,908.85
in general payments reported to CMS, 2019-2025
24 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $476 · 2022: $1,552 · 2023: $1,182 · 2024: $1,489 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,881.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,233.87 | 2022-2025 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $717.05 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $493.34 | 2023-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.43 | 2021-2025 | Jardiance |
| Abbvie INC. | $418.74 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $323.87 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $257.30 | 2024 | Voquezna |
| Lilly USA, LLC | $245.25 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Pfizer INC. | $197.69 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $187.75 | 2023-2025 | Rexulti |
| Abbott Laboratories | $147.18 | 2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $145.93 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $141.01 | 2022-2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $121.36 | 2022 | |
| Glaxosmithkline, LLC. | $119.52 | 2025 | Arexvy, Shingrix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $114.05 | 2025 | Omnipod |
| Abiomed | $113.24 | 2024 | Impella |
| Exact Sciences Corporation | $108.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $106.07 | 2023 | Dexcom G7 Gss (161) |
| Gilead Sciences, INC. | $105.33 | 2023 | Epclusa |
| Vertex Pharmaceuticals Incorporated | $88.10 | 2024-2025 | |
| Argenx US, INC. | $20.41 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $20.02 | 2025 | |
| Acadia Pharmaceuticals INC | $16.76 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.